We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZBAI:NASDAQATIF Holdings Limited Analysis

Data as of 2026-05-12 - not real-time

$8.82

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ATIF Holdings (ZBAI) trades at $8.82, comfortably above its 20‑day SMA of $8.13 and 200‑day SMA of $7.25, indicating short‑term price strength, yet the MACD histogram is negative and the signal line is bearish, suggesting momentum may be turning lower. The RSI sits at 61, still in the bullish zone but approaching overbought levels, while volume has been decreasing, hinting at waning participation. Fundamentally, the company shows a price‑to‑sales ratio of 75.8 and a price‑to‑book of 1.2, but it reports zero profit margin, negative EBITDA, and negative cash flows despite a sizable cash balance of $9.1 M and no debt. Recent news highlights an acquisition intent for Metra Group and a new advisory agreement to expand into digital‑asset consulting, which could provide a growth catalyst but also adds regulatory and execution risk. Overall, the stock appears overvalued relative to its earnings profile, exhibits extreme short‑term volatility (93% 30‑day), and faces a high max drawdown history, making it a risky play at current levels.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and signal line
  • Decreasing volume trend
  • Extremely high price‑to‑sales ratio indicating overvaluation

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Acquisition of Metra Group could broaden service offering
  • New digital‑asset advisory agreement adds growth potential
  • Strong cash position provides a cushion despite negative earnings

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Sustained negative profitability and cash flow
  • High historical volatility and large drawdown
  • Elevated regulatory exposure in capital‑markets consulting

Key Metrics & Analysis

Financial Health

Revenue Growth177.80%
ROE-80.54%
ROA-7.83%
P/B Ratio1.2
Op. Cash Flow$-2457396
Free Cash Flow$-859151
Industry P/E16.5

Technical Analysis

TrendNeutral
RSI61.5
Support$5.91
Resistance$9.27
MA 20$8.13
MA 50$6.98
MA 200$7.25
MACDBearish
VolumeDecreasing
Fear & Greed Index88.02

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.46
Volatility93.40%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.